Third Harmonic Bio will lay off half of its workforce, the biotech has said as it prepares to take its chronic spontaneous urticaria (CSU) candidate into phase 2. The company announced results for a ...

SAN FRANCISCO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced ...

Not only has Third Harmonic pulled off a stock sale, but it was also able to boost the deal size. Wednesday evening, the biotech offered 10.9 million shares priced at $17 each, which was the midpoint ...

1 Main Capital, a boutique investment firm, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned (3.6)% net in the first quarter compared to ...

Cambridge, Massachusetts-based Third Harmonic did not set any financial terms for the stock sale outlined in the preliminary IPO paperwork filed with regulators on Tuesday. However, IPO research firm ...

-- Multiple chemically distinct, next-generation oral KIT inhibitors in exploratory toxicology studies; on track to nominate development candidate in 2023 The Company is initiating nonclinical studies ...

Third Harmonic Bio discontinuing its chronic inducible urticaria program after its only asset failed in a phase 1 safety trial paralyzes its clinical pipeline. Shareholders are now waiting on a ...

CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for ...

Third Harmonic Bio is braving the frosty IPO waters. With the weakest quarter for biotech IPOs in years still fresh in the memory, and the proceeds of a $105 million series B still in its bank account ...

Third Harmonic Bio Inc (NASDAQ:THRD) shares are soaring on Monday after the company announced a plan of liquidation and dissolution. What Happened: Third Harmonic announced that its board approved and ...